ClinicalTrials.gg
RecruitingNCT07038889Updated Oct 15, 2026

Overground Virtual Reality (VR) Gait Rehabilitation for Traumatic Brain Injury (TBI)

An interventional study of C-Mill VR+ by Motek and Walk-over-Ground in Traumatic Brain Injury, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Brain Injuries, Traumatic by Indiana University — 2 open to participants now, 3 under way, none of them phase 3. Brain Injuries, Traumatic · Indiana University.

Planned enrollment
6th of 12
30 · median 29
Started
2026
with 1 other
No phase
11 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Brain Injuries, Traumatic by Indiana University, this one is the 6th largest by planned enrollment, is one of 2 that started in 2026, is one of 11 with no phase, and was the 11th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

2 of the 12 studies in Brain Injuries, Traumatic by Indiana University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brain Injuries, Traumatic by Indiana University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate a new virtual reality (VR)-based rehabilitation program designed to help individuals with traumatic brain injury (TBI) improve their walking abilities in real-world settings. By comparing immersive VR-assisted overground gait therapy to contemporary non-immersive, treadmill-based VR therapy (i.e., C-Mill), the investigators aim to determine its effectiveness in enhancing mobility and quality of life for TBI patients.

Read the detailed description

After obtaining consent and screening, eligible participants are randomized to the treatment or control groups.

First, all participants are issued a wearable tracker to gauge baseline activity for at least 5 days.

During the intervention phase, participants undergo 12 treatment sessions, 2x a week for 6 weeks.

Assessments are conducted at pre-intervention, post-intervention, and 1-month followup.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Gait Training
  • Virtual Reality
  • Traumatic Brain Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis: A confirmed diagnosis of traumatic brain injury (TBI), confirmed by the referring physician.
  • Cognitive Function: (MMSE) score ≥ 24 or Montreal Cognitive Assessment (MoCA) score ≥ 20, indicating sufficient cognitive function to participate in the study.
  • Exercise Clearance: Approval from a physician for participation in exercise-based interventions.
  • Rehabilitation Need: Demonstrates a need for functional rehabilitation.
  • Recent Therapy: Participants should not have received physical therapy (PT) within the last month.
  • Consent: Must be able to provide for themselves.

Exclusion criteria

Exclusion Criteria:

  • Participants with unstable medication regimens that could interfere with their participation in the study.
  • Any comorbidity that could interfere with walking or gait training.
  • Participation in VR-assisted gait training within the last 6 months.
  • Intolerance to virtual reality environments or motion simulation.
  • Severe cognitive, visual, or hearing impairments where the participant cannot follow the therapist's instructions.
  • More than 135 kg total body weight.
  • More than 2.00 meters in body height.
  • Presence of open skin lesions or bandages in areas that would come into contact with the harness.
  • Functional Ambulation Category (FAC): Participants with an FAC score of less than 2 indicate they require physical support from more than one person to walk.

Clarification:

- The diagnosis of TBI can be confirmed by their physician or a physical therapist referring to the patient. If a physical therapist makes the referral, the diagnosis must still be officially confirmed by a physician to ensure it meets the study's medical criteria.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    VR-Assisted Overground Gait Therapy

    Participants in the treatment group (VG-AOGT) will engage in gait training within a newly developed immersive virtual reality (VR) environment. This setup features self-propelled overground walking influenced by three different virtual environments designed to mimic real-world conditions. The immersive technology used is HTC VIVE Focus Vision, enabling participants to practice walking in real-world environments and gait tasks.

    Device: Walk-over-Ground

  • Active comparator
    Conventional Treadmill-Based VR Gait Therapy

    Participants in the control group (VR-CTGT) will engage in gait training using C-Mill VR+ technology, which involves treadmill-assisted walking on a treadmill while interacting with less immersive virtual scenarios presented on screens.

    Device: C-Mill VR+ by Motek

Interventions

  • DeviceC-Mill VR+ by Motek

    Participants perform treadmill-assisted walking while interacting with non-immersive, game-like environments displayed on screens attached to the treadmill.

  • DeviceWalk-over-Ground

    This intervention utilizes the HTC VIVE Focus Vision system for a realistic, fully immersive VR-assisted overground gait therapy. The immersive VR environment is designed to mimic real-world scenarios and challenges, enhancing the rehabilitation process by engaging patients in naturalistic gait activities.

06

What researchers measure

Primary outcomes

  1. Step Count

    FitBit tracks the number of steps (count) taken by participant.

    Time frame: Continuous tracking from Screening to Week 10

  2. Travel Distance

    FitBit tracks the total distance (miles) travelled by participant.

    Time frame: Continuous tracking from Screening to Week 10

  3. Activity Zone Minutes

    Fitbit calculates maximum heart rate (HR) from user age (Max HR = 220 - age) and defines Activity Zone thresholds based on percentages of max HR (Fat Burn 50-69%, Cardio/Peak \>70%). Activity Zone Minutes (AZMs) are an intensity-weighted measure of activity. AZM (count) is based on sustained heart rate over time: 1 AZM per minute in the Fat Burn Zone (50-69% max HR) and 2 AZMs per minute in the Cardio/Peak Zones (\>=70% max HR).

    Time frame: Continuous tracking from Screening to Week 10

Secondary outcomes

  1. 10-Meter Walk Test

    10MWT: Subjects will walk a distance of 10 meters at their normal pace while being timed, allowing assessment of gait speed and mobility. (5 minutes)

    Time frame: Baseline, Week 7, Week 10

  2. 6-Minute Walk Test

    6MWT: Subjects will walk for 6 minutes along a 30m track. Subjects may stop and rest as often as needed. Subject walking speed will be collected during the test to evaluate the rate of functional fatigue. (10 minutes)

    Time frame: Baseline, Week 7, Week 10

  3. Mini-Balance Evaluation Systems Test

    Mini-BESTest: Subjects will complete 14 different tasks ranging from static standing to dynamic walking. All subjects will be guarded closely for safety to prevent falling. (15 minutes)

    Time frame: Baseline, Week 7, Week 10

  4. Timed Up and Go Test

    TUG: Subjects will rise from a seated position, walk three meters, turn around, walk back to the chair, and sit down. This test is used to assess mobility, balance, walking ability, and fall risk. (5 minutes)

    Time frame: Baseline, Week 7, Week 10

  5. Step-Over Test

    SOT: Patients will walk over a flat firm surface for 14 meters. The pathway will include a box that is one foot wide. Each participant will complete 10 passes, stepping over the obstacle (box) each time taking about 15 minutes.

    Time frame: Baseline, Week 7, Week 10

  6. Step Length

    With the PKMAS Zeno Walkway (ProtoKinetics), participants walk over a 14-foot pressure mat to capture gait kinematics. Step length (centimeters) measures the distance between the heel contact point of one foot to the heel contact point of the other foot.

    Time frame: Baseline, Week 7, Week 10

  7. Stride Length

    With the PKMAS Zeno Walkway (ProtoKinetics), participants walk over a 14-foot pressure mat to capture gait kinematics. Stride length (centimeters) measures the distance between successive heel contact points of the same foot.

    Time frame: Baseline, Week 7, Week 10

  8. Stance Percentage

    With the PKMAS Zeno Walkway (ProtoKinetics), participants walk over a 14-foot pressure mat to capture gait kinematics. During the gait cycle, each foot alternates between being in contact with the ground (stance phase) and not in contact with the ground (swing phase). Stance percentage (percent) is the proportion of the gait cycle during which a foot remains in the stance phase.

    Time frame: Baseline, Week 7, Week 10

  9. Gait Speed

    With the PKMAS Zeno Walkway (ProtoKinetics), participants walk over a 14-foot pressure mat to capture gait kinematics. Gait speed (meters per second) is calculated by dividing the distance walked (meters) by the time taken (seconds).

    Time frame: Baseline, Week 7, Week 10

Other outcomes

  1. Disability Rating Scale

    DRS: Participants will complete a questionnaire assessing the level of disability and functional impairment. NOTE: Only applicable to TBI participants.

    Time frame: Screening, Baseline, Week 7, Week 10

  2. Quality of Life after Brain Injury

    QoLIBRI: Participants will complete a questionnaire assessing the health-related quality of life specifically tailored for individuals recovering from brain injury.

    Time frame: Baseline, Week 7, Week 10

  3. Activities-specific Balance Confidence Scale

    ABC: Participants will complete a questionnaire assessing perceived balance confidence during common daily activities.

    Time frame: Baseline, Week 7, Week 10

  4. Cybersickness in Virtual Reality Questionnaire

    CSQ-VR: Assesses physical symptoms associated with VR exposure, including nausea, dizziness, disorientation, and fatigue.

    Time frame: Week 1 and Week 6

  5. Igroup Presence Questionnaire

    IPQ: Measures the user's sense of presence and immersion in VR, such as perceived realism and awareness.

    Time frame: Week 1 and Week 6

  6. Perceived Walking Experience Questionnaire

    PWEQ: Compares walking in VR with real-world walking in terms of comfort, gait differences, and safety concerns. Derived from Horsak et al. (2021) "Overground Walking in a Fully Immersive Virtual Reality".

    Time frame: Week 1 and Week 6

  7. Virtual Reality System Usability Questionnaire

    VRSUQ: Assesses the usability of the VR system, including responsiveness, clarity, and learnability.

    Time frame: Week 1 and Week 6

  8. NASA Task Load Index

    NASA-TLX: Measures perceived task workload.

    Time frame: Week 1 and Week 6

  9. Interview

    Participants will take part in 30-minute semi-structured interviews to share their thoughts on the user experience (e.g. engagement, utility, realism) and provide feedback to improve the virtual reality system.

    Time frame: Week 1 and Week 6

07

Study locations

1 of 1 sites recruiting
  • Indiana University Health, Neurorehabilitation & Robotics
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Peter Altenburger, Ph.D., PT · Contactpaltenbu@iu.edu · 317-278-0703
    • Kathryn Gyves, PT, DPT, NCS, CSRS, AVPT, CBIS · Contactkgyves@iuhealth.org · 317-963-7050
    • Peter Altenburger, Ph.D., PT · Principal investigator
    • Hee-Tae Jung, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 8 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 26, 2025
StartActual
Oct 9, 2026was Aug 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
Indiana University Health, Neurorehabilitation & Robotics is now Recruiting
Oct 15, 2026
Start date
Aug 2026→Oct 9, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Indiana University Health, Neurorehabilitation & Robotics is now Recruiting
    Start date Aug 2026→Oct 9, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07038889
Lead sponsor
Indiana University
Collaborators
Indiana University Health
Responsible party
Hee-Tae Jung (Assistant Professor, Health Informatics, Indiana University) — Principal investigator
First posted
Jun 26, 2025
Start date
Oct 9, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Peter Altenburger, Ph.D., PT
Contact
paltenbu@iu.edu
317-278-0703
Hee-Tae Jung, Ph.D.
Contact
heetjung@iu.edu
317-278-1285
Hee-Tae Jung, Ph.D.
principal investigator · Indiana University, Luddy School of Informatics, Computing, and Engineering
Peter Altenburger, Ph.D., PT
principal investigator · Indiana University, School of Health & Human Sciences; Indiana University Health, Center for Advanced Neurorehabilitation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion